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ABSTRACT 
 
Pregestational diabetes is highly associated with increased risk of birth defects. However, 
factors that can increase or reduce expressivity and penetrance of malformations in 
diabetic pregnancies remain poorly identified. All-trans retinoic acid (RA) plays crucial 
roles in embryogenesis. Here, we find that Cyp26a1, which encodes a key enzyme for 
catabolic inactivation of RA required for tight control of local RA concentrations, is 
significantly down-regulated in embryos of diabetic mice. Embryonic tissues expressing 
Cyp26a1 show reduced efficiency of RA clearance. Diabetes-exposed embryos are thus 
sensitized to RA and more vulnerable to the deleterious effects of increased RA 
signalling. Susceptibility to RA teratogenesis is further potentiated in embryos with a 
pre-existing genetic defect of RA metabolism. Increasing RA clearance efficiency by a 
pre-conditioning approach can counteract the increased susceptibility to RA 
teratogenesis in embryos of diabetic mice. Our findings provide new insight into 
gene-environment interactions that influence individual risk in manifestation of 
diabetes-related birth defects, and shed light on the environmental risk factors and genetic 
variants for a stratified medicine approach to screen diabetic women of childbearing age 
and assess risk of birth defects during pregnancy.  
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Offspring of women with pregestational diabetes show markedly increased risk of 
birth defects (1). While the cause of diabetic embryopathy is known to be multifactorial, 
previous investigations mainly focussed on the effect of maternal diabetes alone on the 
embryo. Genetic and environmental factors that can influence expressivity and 
penetrance of congenital malformations in diabetic pregnancies remain far from clear 
(2,3). Interestingly, some malformations found in the offspring of diabetic mothers (4-6) 
are very similar to those anomalies in humans and animals arising from exposure to 
excess retinoids (vitamin A and its analogues) (7-9). For instance, a large-scale study of 
18 population-based congenital anomaly registries shows that the odds ratio for caudal 
regression in diabetic versus non-diabetic pregnancy (odds ratio: 26.4; 95% confidence 
interval: 8.98-77.64) is well above other malformations (4), which strengthens the 
conclusion of previous studies that caudal regression is a characteristic anomaly 
associated with diabetic pregnancy (5,6). Caudal regression also commonly occurs with 
retinoid teratogenesis in animal studies (9-11).   
 Many of the functions of vitamin A in embryogenesis are mediated via its 
metabolite all-trans retinoic acid (RA), which is a key signalling molecule controlling the 
development of multiple organ systems. Different embryonic tissues/organs show 
variations in requirement for RA, thus tight regulation of local RA concentrations is 
critical to ensure precise levels of RA signalling required for normal embryo 
development. An important mechanism to control local RA concentrations is via 
catabolic inactivation by the CYP26 enzymes belonging to the cytochrome P450 family. 
Three Cyp26 genes, namely Cyp26a1, b1 and c1, are expressed in specific embryonic 
tissues and attenuate deleterious effects of excessive RA signalling. Among them, 
CYP26A1 is the key RA catabolizing enzyme in many tissues and the only subtype that 
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is expressed in the tailbud region of the embryo (12), where caudal regression arises (11). 
Homozygous deletion of Cyp26a1
 
in mice results in lethality at mid-late gestation, with 
embryos exhibiting caudal truncation (13,14). Similarly, we and others have 
demonstrated that mouse embryos exposed to excess RA develop caudal truncation and 
various phenotypes, including specific renal, anorectal, caudal spinal cord and lower 
extremity malformations (10,11,15) commonly associated with caudal regression in 
humans (16,17). Moreover, we find that maternal diabetes potentiates the effect of RA to 
cause caudal regression in mice (18). This similarity in phenotypes resulting from genetic 
and environmental disturbances therefore led us to speculate that maternal diabetes may 
perturb embryonic CYP26A1 function in maintaining a tight regulation of local RA 
concentrations in specific tissues. We hypothesized that such tissues will be vulnerable to 
perturbation of RA levels and exhibit increased susceptibility to RA teratogenesis. Here, 
we provide evidence to support this hypothesis using a mouse model of pregestational 
diabetes. Notably, our findings show that interaction between a genetic predisposition 
and an environmental agent to disrupt RA homeostasis can potentiate maternal 
diabetes-induced deregulated RA catabolism in increasing malformation risk.  
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RESEARCH DESIGN AND METHODS  
 
Animals  
All animal experimentation was conducted following the guidelines set by The Chinese 
University of Hong Kong. Diabetes was induced in ICR female mice by streptozotocin 
injections according to our established protocols (18). Mice with blood glucose 
concentration ≥16.7 mmol/L were classified as manifestly diabetic (MD). Untreated, 
age-matched female ICR mice were employed as the non-diabetic (ND) control. Mice 
were kept in a 12:12 h light-dark cycle with the light cycle commenced at 11:00am. 
Pregnancies were obtained by timed mating for 2 h (9:00-11:00am) between MD/ND 
female ICR mice and male ICR mice, or male Cyp26a1
+/-
 mice in 129/C57BL/6Cr/DBA 
mixed background (a gift from Prof. Hamada, 14). The time of finding a copulation plug 
at 11:00am was defined as embryonic day (E) 0. Mice were checked for blood glucose 
levels prior to embryo collection to confirm that MD mice remained diabetic during 
pregnancy (Supplementary Table 1). 
 
Gene Expression 
Whole embryos were subjected to in situ hybridization (ISH) for Cyp26a1, Cyp26b1 or 
Cyp26c1 with digoxygenin-labeled RNA probes (19). The mRNA expression levels of 
various genes were determined by real-time qRT-PCR. To minimize differences in 
expression levels due to variations in the developmental stage, only embryos within the 
same somite-range (9-10 somite-stage for E8 embryos; 19-21 somite-stage for E9 
embryos) in each litter were collected. This criterion was adopted for embryo collection 
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in other experiments. For crossing between ICR male and ICR female mice, all embryos 
at appropriate somite-stage from the same litter were pooled as one sample. For crossing 
between Cyp26a1
+/-
 male and ICR female mice, embryos were individually collected. 
After DNA genotyping of the yolk sac by PCR using primers as described (14), embryos 
of the same genotype (Cyp26a1
+/+ 
or Cyp26a1
+/-
) from the same litter were pooled as one 
sample. Total RNA was extracted from the whole embryo or tailbud (defined as the 
caudal end of the embryo up to one somite-length posterior to the last somite) samples 
using the RNeasy Mini Kit (Favorgen). An equal amount of RNA (250 ng) was 
reverse-transcribed into first-strand cDNA using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). The cDNA yielded from reverse transcription of 
1.67 ng RNA was subjected to quantitative PCR using ABI 7900HT Fast Real-Time PCR 
system (Applied Biosystems), with SYBR Green PCR Master Mix (Applied Biosystems). 
β-actin was used as internal control for normalization. The PCR conditions and primer 
sequences were listed in Supplementary Table 2.  
 
In Vitro RA Degrading Efficiency 
Using an assay modified from Yamamoto (20), four tailbuds of E9 embryos from the 
same litter were pooled as one sample and lysed in 5 µl of DMEM by trituration with a 
pipette tip, followed by 5 cycles of freezing in liquid nitrogen and thawing in a water bath 
at 37
o
C for 1 min. The whole lysate was added to 50 µl of a reaction mixture containing 
50 nM all-trans RA (Sigma-Aldrich), with or without 1.6 mg/ml NADPH (cofactor of 
cytochrome P450 enzyme), 0.3 mg/ml DTT (reducing agent for optimal cytochrome 
P450 enzyme function) and CYP26 specific inhibitor R115866 (21) at a concentration of 
1, 10 or 100 nM in a culture medium (DMEM supplemented with 10% fetal bovine 
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serum). The reaction mixture was then incubated in a 5% CO2 incubator at 37
o
C for 2 h, 
during which the exogenous RA in the medium was degraded by the RA catabolizing 
enzyme in the tailbud lysate. After incubation, the amount of RA remaining was 
determined by adding the reaction mixture, diluted 30-fold with the culture medium, in 
triplicate to a 96-well plate containing RA reporter cells, which are F9 cells transfected 
with a RA response element that drives β-galactosidase expression (22). Serially diluted 
RA standard solutions at concentrations from 10
-6
M to 10
-11
M were added in triplicate to 
the same 96-well plate. After culturing for 24 h, cells were stained with X-gal and the 
intensity of the blue product was measured using a microplate spectrophotometer. RA in 
the sample was quantified using a standard curve constructed with the serially diluted RA 
solutions (Supplementary Figure 1). 
 
In Vivo Clearance of RA 
To determine in vivo efficiency of RA clearance, at various time points post-injection of 
50 mg/kg body weight of RA at E9, the tailbud was collected under dim yellow light. 
Tailbuds were individually placed in 300 µl of the culture medium added with 100 nM 
R115866 to inhibit endogenous CYP26 enzymes. After 24 h of incubation in 5% CO2 at 
37
o
C, to allow maximum release of RA from the tailbud into the medium, RA in the 
medium was quantified using the RA reporter cell line. A preliminary study demonstrated 
that the culture conditions did not cause significant degradation of RA (Supplementary 
Figure 2). To validate that RA measured using the RA reporter cell line measures RA 
released from tissues that can modulate RA levels, the tailbud of E9 embryos was 
collected 3 h post-injection of RA. The midbrain, which does not express any Cyp26 
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genes in untreated or RA-treated conditions, was also collected from these embryos as a 
control. Tissues from the same litter were pooled as one sample. RA in the sample was 
quantified using HPLC (23). 
 
Detection of Bioactive RA in Tailbud 
The caudal-most portion of the tailbud of E9 embryo of MD and ND mice was excised 
under dim yellow light and individually placed on top of RA reporter cells grown on a 
96-well plate in the culture medium added with 100 nM R115866 to inhibit endogenous 
CYP26 enzymes. After 24 h of culture, cells were stained with X-gal. The number of 
positively stained cells around the tailbud explant was counted under a stereomicroscope.    
 
Susceptibility to RA Teratogenesis 
The teratogenic effect of RA is dose- and stage-dependent (9). To determine the 
susceptibility to RA teratogenesis, MD or ND mice at E8 or E9 received an 
intraperitoneal injection of 25 mg/kg RA or equivalent volume of suspension vehicle 
(peanut oil) as a control, and their embryos were examined at E13. Embryos treated with 
RA at E9 were examined for the extent of caudal truncation, which was expressed as the 
ratio of tail length to crown-rump length as used in our previous studies (18). Embryos 
treated with RA at E8 were examined for exencephaly and spina bifida. Near-term E18 
fetuses maternally treated with 40 mg/kg RA at E9 were examined for various types of 
renal malformations as described in our previous studies (24). Maternal pre-conditioning 
with low dose RA (0.625 or 1.25 mg/kg) or suspension vehicle (peanut oil) as a control 
was achieved by oral gavage 2 h before receiving intraperitoneal injection of teratogenic 
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dose of RA.  
 
Statistics 
Statistical differences between two groups were analyzed by unpaired Student’s t test. 
Differences between multiple groups of data were analysed by one-way ANOVA, 
followed by Bonferroni post-hoc test, or by using Contrast test for assessing extent of 
differences. Dose response was analyzed by linear regression. The best-fit curves were 
compared by nonlinear regression. Data were presented as mean ± SEM, with P < 0.05 
considered as statistically significant. All statistical analyses were conducted using the 
SPSS software (SPSS Inc.), except nonlinear regression analysis, which was conducted 
using the Prism software (GraphPad Software). 
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RESULTS 
 
Cyp26a1 Expression Levels and RA Degrading Efficiency are Reduced in Embryos 
of Diabetic Mice 
During early mouse post-implantation development, Cyp26a1 is initially expressed in 
the headfold mesenchyme (Fig. 1A), and then extends to the caudal neural plate and 
primitive streak (Fig. 1B). As development proceeds, Cyp26a1 expression persists at the 
caudal end (Fig. 1C and D), now called the tailbud, which contains progenitor cells for 
forming various posterior structures. Rostrally, it is expressed in the craniofacial, 
cervical and branchial arch mesenchyme (Fig. 1C). Embryos of manifestly diabetic 
(MD) mice exhibit a significant decrease in Cyp26a1 mRNA transcripts in all of these 
regions compared with embryos of non-diabetic (ND) mice (Fig. 1A-E). In contrast, 
Cyp26b1 and Cyp26c1 are expressed predominantly in the cranial region but not in the 
tailbud (Fig. 1F and H), and show no significant difference in expression levels 
between embryos of MD and ND mice (Fig. 1G and I). 
To determine whether a decrease in Cyp26a1 expression results in reduced 
efficiency of RA catabolism, we employed an in vitro assay to compare the RA 
degrading efficiency of the tailbud, which exclusively expresses Cyp26a1, but not 
Cyp26b1 and Cyp26c1, from E9 embryos of MD and ND mice. Results showed that 
only a low level of RA degrading activity was detected when tailbud lysate alone was 
applied (Fig. 2A). However, in the presence of NADPH and DTT for optimal activity of 
CYP26 enzymes, 66% of added RA was degraded within 2 h. In contrast, co-treatment 
with 1-100 nM of R115866, a potent CYP26-specific inhibitor (21), resulted in a 
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significant dose-dependent inhibition of RA degradation. Notably, while there was no 
significant difference in the protein content of the excised tailbuds from embryos of MD 
and ND mice (Supplementary Figure 3), tailbud lysate of the MD group exhibited only 
45% of activity of the ND group.  
To further compare the efficiency of in vivo clearance of RA, MD and ND mice 
were injected with an exogenous dose of 50 mg/kg RA at E9, followed by measurement 
of RA in individual tailbuds at hourly intervals using the RA reporter cell line (Fig. 2B), 
which showed results comparable with quantification of RA using HPLC 
(Supplementary Table 3). Despite a similar response time-course in MD and ND groups, 
the amount of RA in tailbuds of the MD group was significantly higher than the ND 
group at all time-points studied (Fig. 2B). Moreover, by determining the area under the 
concentration-time curve (AUC), which is considered as the most appropriate 
pharmacokinetic correlate of embryotoxicity of RA (25), there was a two-fold difference 
between MD (AUC0-8h: 25.59 nM x h, calculated by the Prism 5 software, GraphPad 
Software) and ND (AUC0-8h: 12.70 nM x h) groups, implying that the efficiency of in 
vivo RA clearance in tailbuds of diabetes-exposed embryos was reduced by 50%. In 
contrast, the E9 midbrain, which does not express any of the three Cyp26 genes in both 
untreated and RA-treated conditions (Supplementary Figure 4A), exhibited no differences 
in RA levels between embryos of MD and ND mice at 3 h post-injection of RA 
(Supplementary Figure 4B).  
 
RA Levels are Increased in Tailbuds of Embryos of Diabetic Mice 
To determine whether reduction in RA degrading efficiency would lead to a rise in 
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endogenous RA levels, we excised the caudal-most part of the tailbud (Fig. 3A) furthest 
away from the RA source in adjacent trunk tissues, and put it directly on the RA reporter 
cells to detect bioactive RA release (22). Reporter cells exposed to RA expressed 
β-galactosidase and turned blue with X-gal staining. There were hardly any positively 
stained cells around tailbuds from embryos of ND mice (Fig. 3B and C), which agrees 
with previous findings that the tailbud is normally devoid of RA (26). However, stained 
cells were observed around more than half the tailbuds from embryos of MD mice. The 
number of stained cells varied from under 10 to over 40, implying a varying magnitude of 
elevation of RA level in tailbuds of diabetes-exposed embryos. 
Several genes including Fgf8, Wnt3a and Cdx2 are indispensable key players in 
caudal development (27). Excessive RA has been demonstrated to down-regulate these 
genes and cause axial truncation (11,26,28). However, of these genes, only Fgf8 was 
significantly down-regulated in the tailbud of embryos of MD mice (Fig. 4A). It is 
possible that the magnitude of increase in RA levels may not have reached the threshold 
for causing detectable alteration in the expression of some of these genes. We therefore 
challenged embryos with 50 mg/kg of RA to test whether deregulated catabolism of RA 
would sensitize embryos of MD mice to RA. At 4 h post-injection of RA, there was a 
dramatic increase in mRNA levels of Cyp26a1 in the tailbud (Fig. 4B), showing that 
Cyp26a1 is highly inducible by RA. However, the magnitude of up-regulation of 
Cyp26a1 in tailbuds of the MD group was significantly less than the ND group (P < 0.05, 
Contrast test), which further exacerbated the difference between these two groups. 
Concomitantly, there was a marked down-regulation of Fgf8, with expression levels in 
tailbuds of the RA-treated MD group reduced to less than one-third of the ND group 
without RA treatment (Fig. 4C). Consistent with our previous findings (18), though there 
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was no difference in Wnt3a expression levels between tailbuds of MD and ND groups at 
steady-state (Fig. 4A), upon RA challenge, Wnt3a was down-regulated to a significantly 
greater extent in tailbuds of the MD group than the ND group (Fig. 4C). Similarly, the 
MD group showed increased propensity to RA-induced down-regulation of Cdx2. 
RA action is mediated via transactivation by retinoic acid receptors (Rar) that 
heterodimerize with retinoid X receptors (Rxr). In the mouse embryo, Rarγ and Rxrα 
mediate the teratogenic effect of RA in inducing caudal truncation (29,30). However, 
there were no differences in expression levels of Rarγ and Rxrα between tailbuds of 
embryos of ND and MD mice at steady-state (Fig. 4A) or 4 h post-injection of RA (Fig. 
4C). Together, these findings support the idea that enhanced down-regulation of caudal 
regulatory genes in tailbuds of embryos of MD mice is due to increased RA levels 
resulting from reduced efficiency of RA degradation, rather than secondary to differences 
in efficiency of transactivation via the RA receptors.  
 
Genetic Reduction of Cyp26a1 Exacerbates Susceptibility of Embryos of Diabetic 
Mice to RA Teratogenesis 
We asked whether a decrease in Cyp26a1 expression leads directly to reduced efficiency 
of RA clearance, and whether functional loss of Cyp26a1 could interact with the maternal 
diabetic environment to influence RA degrading efficiency and susceptibility to RA 
teratogenesis. To investigate these questions, we crossed Cyp26a1
+/-
 male mice with MD 
or ND female mice. We hypothesized that Cyp26a1
+/-
 mutant embryos would exhibit a 
lower RA degrading efficiency than their Cyp26a1
+/+
 wild-type littermates and that 
exposure to maternal diabetes would exacerbate these genetic differences.  
 Indeed, E9 embryos from different genotype-maternal environment combinations 
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showed prominent differences in Cyp26a1 levels (Fig. 5A). The Cyp26a1 mRNA levels 
in tailbuds of Cyp26a1
+/-
 embryos of MD mice were reduced to half of the level in 
Cyp26a1
+/+
 embryos of ND mice (Fig. 5B), with a corresponding decrease in 
CYP26-mediated RA degrading efficiency (Fig. 5C). When RA levels were raised, via 
maternal challenge with 25 mg/kg of RA, a 50% reduction in Cyp26a1 expression levels 
and RA degrading efficiency in tailbuds of Cyp26a1
+/-
 embryos of MD mice resulted in 
exposure to an eight-fold higher effective concentration of RA in comparison to tailbuds 
of Cyp26a1
+/+
 embryos of ND mice (Fig. 5D). This effect was noted 3 h after RA 
injection, when accumulation of RA had reached peak level (Fig. 2B). In agreement with 
these findings, Cyp26a1
+/-
 embryos of MD mice were most sensitized to RA-induced 
caudal truncation (Supplementary Figure 5), as indicated by the smallest ratio of tail 
length (TL) to crown-rump length (CRL) (Fig. 5E). TL/CRL ratio was used as a 
‘surrogate’ both for regression of multiple caudal structures in mice and for the analogous 
‘caudal regression’ process that affects species without tails, such as humans. In addition 
to caudal truncation, renal malformations are commonly associated with caudal regression 
(15,16). Indeed, we also found a twelve-fold increase in incidence (Fig. 5F) and severity 
(Table 1) of renal malformations in near-term Cyp26a1
+/-
 fetuses exposed to maternal 
diabetes compared with wild-type fetuses in non-diabetic pregnancy when being 
challenged with a teratogenic dose of RA. 
 
Enhancing RA Degrading Efficiency Counteracts Increased Susceptibility to RA 
Teratogenesis Induced by Maternal Diabetes 
Cyp26a1 is highly RA-inducible, as it contains multiple RA response elements (31). Thus, 
as a proof-of-principle, we attempted to ‘pre-condition’ embryos of MD mice by using an 
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exogenous sub-teratogenic RA dose to up-regulate Cyp26a1 expression, in order to 
determine whether pre-conditioning could lead to a protective effect against RA 
teratogenesis. Previous findings showed that maternal oral administration of 2.5 mg/kg 
RA is sufficient to achieve near full rescue of mid-gestation mouse embryos lacking 
Raldh2, the principal RA synthetic enzyme (32). Therefore, we pre-conditioned pregnant 
mice with 0.625 or 1.25 mg/kg RA via oral feeding. These dosages are far below the 
teratogenic concentration range, but yielded a dose-dependent increase in Cyp26a1 
mRNA levels in tailbuds of embryos by 2 h after administration (Fig. 6A). Notably, 
supplementation with 0.625 mg/kg RA did not induce changes in Fgf8, Wnt3a and Cdx2 
expression (Supplementary Figure 6), but up-regulated the expression of Cyp26a1 in 
tailbuds of the MD group to a level similar to that of the ND group fed with vehicle (Fig. 
6A), with a concomitant normalization of RA degrading efficiency (Fig. 6B). Then, when 
maternally challenged with an intraperitoneal injection of a teratogenic dose of 25 mg/kg 
RA, we found the severity of caudal truncation to be significantly reduced, as shown by 
the significantly higher TL/CRL ratio in embryos of RA-pre-conditioned mice than in 
embryos from vehicle-fed mice in both MD and ND conditions (Fig. 6C). Even the 
higher (1.25 mg/kg) pre-conditioning dose of RA was non-teratogenic and by itself did 
not affect the TL/CRL ratio of the embryo. While it could have had other effects on the 
embryo, in addition to up-regulating Cyp26a1, the highly comparable pattern of 
dose-dependent up-regulation of Cyp26a1 and dose-dependent increase in the TL/CRL 
ratio, in the absence of changes in the key caudal regulatory genes, suggests a specific 
effect of pre-conditioning. These findings support the idea that pre-conditioning the 
embryo via enhancing RA degrading efficiency can offer a protective effect against RA 
teratogenesis and abolish the increased propensity of embryos from diabetic pregnancy to 
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RA-induced caudal truncation.  
 Amongst the most frequent congenital anomalies associated with maternal 
diabetes are neural tube defects (NTDs) (4). Expression levels of Cyp26a1 in the cranial 
mesenchyme and the caudal neural plate are prominently reduced in E8 embryos of MD 
mice (Fig. 1B). Moreover, Cyp26a1
-/- 
embryos exhibit exencephaly and spina bifida 
(13,14), suggesting the importance of CYP26A1 enzyme in protecting these tissues from 
the deleterious effects of ectopic RA signalling. We found that injection of 25 mg/kg of 
RA at E8 induced around 6.7% exencephaly (Fig. 7A) and 4.4% spina bifida (Fig. 7B) in 
Cyp26a1
+/+
 embryos of ND mice. However, the incidence of RA-induced exencephaly 
and spina bifida was markedly increased by six- and seven-fold respectively in 
Cyp26a1
+/+
 embryos exposed to diabetes. Similar trend was found in embryos of ICR x 
ICR background (Supplementary Figure 7). The penetrance of NTDs was further 
exacerbated to 75.0% exencephaly and 71.3% spina bifida in Cyp26a1
+/-
 embryos of MD 
mice with a pre-existing genetic defect of RA catabolism. Similar to caudal truncation, 
the increase in susceptibility to RA-induced exencephaly and spina bifida caused by 
maternal diabetes was significantly reduced when embryos were pre-conditioned by 
maternal feeding of low dose RA. Together, these findings support the idea that 
deregulated RA catabolism resulting from reduced levels of Cyp26a1 expression acts to 
sensitize embryos of diabetic pregnancy to fluctuations in RA levels.  
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DISCUSSION 
 
In the present study, we found that the embryonic expression of the key RA catabolizing 
enzyme Cyp26a1 is significantly down-regulated under maternal diabetes. This leads to a 
decrease in RA inactivation efficiency and enhances the deleterious effect of excessive 
RA signalling on key caudal regulatory genes, such as Fgf8, Wnt3a and Cdx2, which are 
required for continued axial elongation (27). We previously demonstrated that enhanced 
RA-induced down-regulation of Wnt3a exacerbated apoptosis in the tailbud of mouse 
embryos exposed to a diabetic or hyperglycemic condition, leading to premature 
termination of caudal development (18,33). This resulted in absence of lower vertebrae, 
imperforate anus, clubfeet, renal and caudal spinal cord malformations, all of which are 
commonly associated with caudal regression (10,11,15-17).     
The most frequent anomalies in pregnancies complicated by pregestational 
diabetes are NTDs and congenital heart defects (CHDs) (4,5). Results of this study 
support the idea that a decrease in Cyp26a1 expression also significantly increases the 
propensity of embryos from diabetic pregnancy to exencephaly and spina bifida when RA 
homeostasis is perturbed. Although we have not examined heart development, Cyp26a1 
is expressed in the cardiac neural crest cells, primitive heart tube and outflow tract, and 
Cyp26a1
-/- 
embryos exhibit CHDs (13,14). Specific subgroups of CHD associated with 
improper RA signalling (8,9) are highly similar to those showing increased frequencies in 
the offspring of mothers with pregestational diabetes (4,34). As tight regulation of RA 
signalling is critical for many developmental processes, deregulated RA catabolism in 
early embryonic life can perturb the development of multiple organ systems, which is in 
line with the finding that specific multiple congenital anomalies are common in affected 
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offspring of mothers with pregestational diabetes (4,5). 
In our diabetic mouse colony, around 5% of embryos developed NTDs. However, 
there are large variations in congenital malformation frequencies between different 
laboratories, with the frequency of NTDs reaching over 50% in some reports (35). While 
genetic background affects the susceptibility to diabetic embryopathy (2,36), recent 
studies demonstrate that different types of rodent chow could significantly alter the 
frequency of NTDs in embryos of diabetic mice, which supports the idea that maternal 
diet is an important modifier of penetrance of malformation (3). Individual malformation 
risk will therefore depend on the interaction between genetic and environmental 
influences, which affects the developmental threshold of gene expression for normal 
development.  
Many genetic and environmental factors can affect embryonic RA homeostasis 
and signalling pathways to potentiate the effect of maternal diabetes in increasing 
malformation risk in the offspring. In humans, genetic polymorphisms of CYP26A1 that 
exhibit significantly lower degrading efficiency of RA have been identified (37,38). 
Duplication and polymorphisms of human ALDH1A2 gene (encoding the principal RA 
synthetic enzyme during embryogenesis) are associated with increase in serum RA levels 
(39) and various types of congenital anomalies including CHDs and NTDs (40). Thus, 
common genetic variants involved in RA metabolism and signalling pathways could 
potentially be used as markers to identify diabetic pregnancies with increased 
malformation risk. 
Retinoids are recognized human teratogens (41). Various forms of retinoids are in 
clinical use or under study for treatment of a variety of diseases, including skin disorders, 
obesity, diabetes and related complications (42). A well-known example is isotretinoin 
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(13-cis RA) prescribed for treatment of severe acne. It has been shown that the 
teratogenic threshold for isotretinoin is much lower in humans (0.5 mg/kg) (43) than in 
mice (100 mg/kg) (44). Human embryos are highly sensitive to isotretinoin, with a 
pattern of malformations (8) similar to that seen in animals exposed to all-trans RA 
teratogenesis (9). In fact, the teratogenic effect of 13-cis RA has been demonstrated in 
animals and suggested for humans to be mediated via its conversion to all-trans RA, 
which then binds to the nuclear RA receptors to regulate gene expression (45). Moreover, 
our previous (18) and present studies show that maternal diabetes can enhance RA 
teratogenicity. Thus the teratogenic threshold for isotretinoin in embryos of women with 
pregestational diabetes may be even lower than the 0.5 mg/kg figure previously quoted 
(43).  
Other than direct exposure to retinoids, medications, such as the anti-convulsant 
valproic acid, and fluconazole for treating fungal and yeast infections, have been shown 
to increase embryonic RA levels and induce malformations (46,47). Maternal smoking 
may also impose increased risk since recent studies suggest that the teratogenic effect of 
nicotine on embryonic development is highly associated with suppression of Cyp26a1 
and perturbation of RA signalling (48). In fact, many chemicals can modulate RA 
homeostasis. As such, neural tube and axial defects mediated by modulation of RA 
homeostasis is proposed to be adopted as an Adverse Outcome Pathway (AOP) 
framework for assessing developmental toxicity of chemicals (49).   
There is a global trend that type 2 diabetes increasingly affects children and 
adolescents (50). As the prevalence of diabetes in women of childbearing age continues 
to rise, the number of pregnancies complicated by pregestational diabetes is likely to 
increase exponentially. The partial penetrance and variable expressivity of diabetic 
Page 19 of 47 Diabetes
 20 
embryopathy underscore its multifactorial nature, implicating interactions between 
genetic make-up of the embryo, maternal factors and environmental influence. It is 
therefore of utmost importance to identify risk factors so as to reduce malformations in 
diabetic pregnancy. The present study is the first to show that RA catabolism is 
deregulated in embryos exposed to diabetes and suggests that pregnancies of diabetic 
women may be more vulnerable to perturbation in RA homeostasis and signalling. This 
may highlight the need to be cautious in assessing the upper safe levels of drugs, 
supplements and potential teratogens for women with pregestational diabetes, particularly 
those that have effects on RA homeostasis and signalling. Association studies should be 
conducted to determine whether specific genetic variants or peri-conceptional exposure to 
environmental agents that perturb RA homeostasis and signalling could be potentiation 
factors that increase individual malformation risk in the offspring of diabetic mothers. 
Identifying these targets could contribute to genetic screening and preventive healthcare 
for diabetic women with childbearing potential. Furthermore, as a proof-of-principle, we 
have demonstrated the protective effect of correcting RA catabolism in embryos of 
diabetic mice. This finding may form the basis for developing stratified medicine to 
reduce the risk of congenital anomalies in pregnancies complicated by pregestational 
diabetes. 
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Table 1. Frequency of various phenotypes (categorized according to the severity of 
malformations) in E18 Cyp26a1 heterozygous null (+/-) and wild-type (+/+) fetuses from 
non-diabetic (ND) and manifestly diabetic (MD) mice induced by in vivo challenge with 40 
mg/kg RA at E9  
 
 
 
Maternal state ND MD 
Genotype of fetuses +/+ +/- +/+ +/- 
No. of litters 11 11 
No. of live fetuses 68 61 48 49 
Two normal kidneys 91.2% 80.3% 62.5% 36.7% 
Unilateral non-agenesis renal malformations 
(contralateral kidney being normal) 
2.9% 9.8% 16.7% 26.5% 
Bilateral non-agenesis renal malformations 2.9% 8.2% 12.5% 10.2% 
Unilateral renal agenesis (solitary kidney being normal) 1.5% 1.6% 0 8.2% 
Unilateral renal agenesis (solitary kidney with 
non-agenesis malformations 
1.5% 0 4.2% 6.1% 
Bilateral renal agenesis 0 0 4.2% 12.2% 
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FIGURE LEGENDS 
 
Figure 1 - Embryos of diabetic mice exhibit specific down-regulation of Cyp26a1. A-D,F 
and H: Whole-mount ISH patterns of Cyp26 genes in embryos of manifestly diabetic 
(MD) mice compared with those of non-diabetic (ND) mice. Cyp26a1 mRNA transcripts 
are seen in extraembryonic endoderm (red arrowhead) and headfold mesenchyme (yellow 
arrowhead) of E7 conceptuses (A), cranial mesenchyme (green arrowhead) and caudal 
neural plate (orange arrowhead) of E8 embryos (B), craniofacial, cervical and branchial 
arch mesenchyme (circled) (C), and tailbud (blue arrowhead) of E9 embryos (D). 
Cyp26b1 (F) and Cyp26c1 (H) are expressed in the cranial but not in the tailbud region of 
E9 embryos. At least 20 embryos from 5-6 litters were examined for each group. Scale 
bar = 0.05 mm (A), 0.1 mm (B), 0.7 mm (C), 0.2 mm (D), 0.7 mm for whole embryo and 
0.35 mm for caudal region (F and H). E,G,I: Quantification of mRNA levels of Cyp26a1 
(E), Cyp26b1 (G) and Cyp26c1 (I), normalized to β-actin, and expressed relative to ND, 
which was set as 1 (n = 5 from 5 litters). *P < 0.05, Student’s t test. Error bars represent 
mean ± SEM. 
 
Figure 2 - Embryos of diabetic mice show reduced efficiency of RA catabolism. A: In 
vitro RA degrading efficiency, presented as % of RA in the medium being degraded by 
the tailbud lysate, in the presence or absence of cofactor (NADPH) and reducing agent 
(DTT) for optimal activity of CYP26 enzymes, and varying concentrations of R115866 
(CYP26 inhibitor) (n = 18 in ND and MD groups with NADPH-DTT, and n = 3-9 in 
other groups, from 20 ND and 18 MD litters). *P < 0.001, Student’s t test; 
†
R
2 
= 0.742 
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and P = 0.001, linear regression. B: In vivo RA clearance measured as the amount of RA 
released from individual tailbuds, using a RA reporter cell line, at hourly intervals after 
injection of 50 mg/kg RA at E9 (n = 16-42 from 3-8 litters). *P < 0.001 vs ND; Student’s 
t test and nonlinear regression. Error bars represent mean ± SEM. 
 
Figure 3 - Tailbuds of E9 embryos of diabetic mice have increased levels of endogenous 
RA detected using a RA reporter cell line. A: Figure to illustrate the caudal-most portion 
of the tailbud (boundary marked by dotted line) as excised for detection of bioactive RA. 
B: Percentage of tailbuds excised from embryos of non-diabetic (ND) and manifestly 
diabetic (MD) mice that have induced different numbers of positively stained cells in the 
RA reporter cell line (n = 19 for ND and 22 for MD from 3 and 4 litters respectively). C: 
Representative figures of excised tailbuds that were placed directly on the RA reporter 
cells and have induced different numbers of stained cells in the RA reporter cell line.   
 
Figure 4 - Tailbuds of E9 embryos of diabetic mice exhibit a greater magnitude of 
suppression of key genes for caudal development induced by RA. A: Quantification of 
mRNA levels of various caudal regulatory genes and RA nuclear receptors, normalized to 
β-actin, and expressed relative to ND, which was set as 1, in tailbuds of embryos of 
non-diabetic (ND) and manifestly diabetic (MD) mice at E9 (n = 5 from 5 litters). **P < 
0.01, Student’s t test. B and C: Quantification of mRNA levels of Cyp26a1 (B), and 
various caudal regulatory genes and RA nuclear receptors (C), normalized to β-actin, and 
expressed relative to ND (CON), which was set as 1, in tailbuds of embryos of ND and 
MD mice 4 h after maternal injection of 50 mg/kg RA (50RA) or vehicle as control (CON) 
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at E9 (n = 5 from 5 litters). *P < 0.05; **P < 0.01; ***P < 0.001, one-way ANOVA 
followed by Bonferroni test. Error bars represent mean ± SEM. 
 
Figure 5 - Cyp26a1 loss of function genotype interacts with diabetic maternal 
environment to influence RA degrading efficiency and susceptibility to RA teratogenesis. 
A: Whole-mount ISH patterns of Cyp26a1 expression in Cyp26a1 heterozygous null (+/-) 
embryos and their wild-type (+/+) littermates from non-diabetic (ND) and manifestly 
diabetic (MD) mice at E9. At least 30 embryos from 6-8 litters were examined for each 
group. Scale bar = 0.25 mm. B: Quantification of Cyp26a1 mRNA, normalized to β-actin, 
and expressed relative to ND (+/+), which was set as 1, in tailbuds of embryos from 
different genotype-maternal environment combinations at E9 (n = 5 from 5 litters). C: In 
vitro RA degrading efficiency, presented as % of RA in the medium being degraded by 
the tailbud lysate in the absence or presence of 100 nM R115866 (CYP26 inhibitor) (n = 
8-13 from 10-14 litters). D: Quantification of RA released from individual tailbuds, using 
a RA reporter cell line, at 3 h after in vivo challenge with 25 mg/kg RA (25RA) at E9 (n = 
22-28 from 6-7 litters). E: Maternal injection of 25 mg/kg RA (25RA) or vehicle as 
control (CON) at E9. Caudal truncation, measured in terms of the ratio of tail 
length/crown-rump length (TL/CRL), was examined in E13 embryos (n = 41-62 from 10 
litters). F: Maternal injection of 40 mg/kg RA (40RA) or CON at E9. Near-term E18 
fetuses were examined for renal malformations (n = 11 litters). *P < 0.05; **P < 0.01; 
***P < 0.001, one-way ANOVA followed by Bonferroni test. Error bars represent mean ± 
SEM. 
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Figure 6 - Pre-conditioning with low dose RA up-regulates Cyp26a1, increases RA 
degrading efficiency, and protects against RA-induced caudal truncation. A: 
Quantification of Cyp26a1 mRNA, normalized to β-actin, and expressed relative to ND 
(CON), which was set as 1, in tailbuds of E9 embryos from non-diabetic (ND) and 
manifestly diabetic (MD) mice 2 h after maternal oral feeding with low dose RA of 0.625 
mg/kg (0.625RA) or 1.25 mg/kg (1.25RA), or with vehicle as control (CON) (n = 5 from 
5 litters). B: In vitro RA degrading efficiency, presented as % of RA in the medium being 
degraded by the tailbud lysate from embryos with or without preconditioned with 
0.625RA (n = 5 from 3-5 litters). C: Embryos, with or without preconditioned with low 
dose RA, were maternally challenged with a teratogenic dose of 25 mg/kg RA (25RA) at 
E9, and examined for caudal truncation, measured in terms of the ratio of tail 
length/crown-rump length (TL/CRL) at E13 (n = 34-60 from 3-5 litters). *P < 0.01; **P < 
0.001, Student’s t test. 
†
R
2
 = 0.900 and P < 0.001; 
††
R
2
 = 0.869 and P < 0.001; 
†††
R
2
 = 
0.610 and P < 0.001; 
††††
R
2
 = 0.729 and P < 0.001, linear regression. Dotted line 
represents no significant difference between the two groups. Error bars represent mean ± 
SEM. 
 
Figure 7 - Increased susceptibility of embryos of diabetic mice to RA-induced neural 
tube defects is abolished by pre-conditioning with low dose RA. A and B: Incidence rates 
of exencephaly (A) and spina bifida (B) in E13 Cyp26a1 heterozygous null (+/-) and 
wild-type (+/+) embryos from non-diabetic (ND) and manifestly diabetic (MD) mice (n = 
8-9 litters). Effect of pre-conditioning by oral feeding of low dose 0.625 mg/kg RA 
(0.625RA) is compared with vehicle-fed control (CON) or no treatment (NT) group, 2 h 
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prior to in vivo challenge with a teratogenic dose of 25 mg/kg RA (25RA) at E8. *P < 
0.05; **P < 0.01; ***P < 0.001, one-way ANOVA followed by Bonferroni test. Dotted line 
represents no significant difference between the two groups. Error bars represent mean ± 
SEM. 
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Supplementary Figure 1. A representative standard curve showing the response of
the RA reporter cell line to serially diluted RA solutions from 10-6M to 10-11M. A
linear dose-response is present from 10-7M to 10-10M. RA concentration of the sample
was plotted against the standard curve within the linear range. R2 represents the
coefficient of determination for linear regression analysis.
R2 = 0.9994
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Supplementary Figure 2. RA was stable at 37°C for 24 h. RA was added to the
culture medium at a concentration of 10 nM. The medium was either immediately
frozen and stored at -80°C (n = 4) or incubated at 37°C for 24 h in a 5% CO2 incubator
(n = 4). The RA concentrations of the two groups of samples were then determined by
the RA reporter cell line. There was no significant degradation of RA in the sample
that had been incubated at 37°C for 24 h when compared with the immediately frozen
sample.
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Supplementary Figure 3. No significant difference in the protein content of the
excised tailbuds from embryos of non-diabetic (ND) and manifestly diabetic (MD)
mice. Total protein in individual tailbuds measured using Bradford assay (n = 18-20
from 3 litters). Error bars represent mean ± SEM.
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Supplementary Figure 4. The midbrain, which does not express any of the three
Cyp26 genes, exhibits no difference in RA levels between embryos of diabetic and
non-diabetic mice after RA treatment. A: In situ hybridization on E9 embryos
demonstrates that all three Cyp26 genes (Cyp26a1, Cyp26b1 and Cyp26c1) do not
express in the midbrain (MB) with or without (No RA) being maternally treated with
50 mg/kg RA (50RA). Scale bar = 0.4 mm. B: Amount of RA in the tailbud and
midbrain of E9 embryos 3 h post-injection of 50RA, measured using HPLC (n = 7-9
from 7-9 litters). The tailbud of embryos of manifestly diabetic (MD) mice with
reduced Cyp26a1 expression had a significantly greater amount of RA than in
embryos of non-diabetic (ND) mice. In contrast, the midbrain, without Cyp26
expression, showed no difference in the amount of RA between embryos of MD and
ND mice. *P < 0.001, Student’s t test. Error bars represent mean ± SEM.
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Supplementary Figure 5. Heterozygosity for Cyp26a1 loss of function exacerbates
increased susceptibility to RA-induced caudal truncation in embryos exposed to
diabetes. Morphology of the caudal region of E13 Cyp26a1 heterozygous null (+/-)
embryos and their wild-type (+/+) littermates from non-diabetic (ND) and manifestly
diabetic (MD) mice that were challenged in vivo with 25 mg/kg RA (25RA) or vehicle
as control (CON) at E9. Embryos of different genotype-maternal environment
combinations showed prominent differences in susceptibility to RA-induced caudal
truncation. Scale bar = 0.1 cm.
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Supplementary Figure 6. Oral feeding of low dose RA does not cause any change in
expression of key genes for caudal development. Quantification of mRNA levels of
various caudal regulatory genes, normalized to β-actin, and expressed relative to ND
(CON), which was set as 1, in tailbuds of E9 embryos of non-diabetic (ND) and
manifestly diabetic (MD) mice, 2 h after oral feeding with low dose 0.625 mg/kg RA
(0.625RA) or vehicle as control (CON) (n = 5 from 5 litters). No significant changes
in mRNA levels were associated with low dose RA treatment. *P < 0.05, one-way
ANOVA followed by Bonferroni test. Error bars represent mean ± SEM.
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Supplementary Figure 7. Incidence of exencephaly in E13 embryos (ICR♂x ICR♀
genetic background) from non-diabetic (ND) and manifestly diabetic (MD) mice with
or without (No RA) in vivo challenge with 25 mg/kg RA (25RA) at E8 (n = 9-12
litters). In untreated conditions, only 3% of embryos of MD mice developed
exencephaly. However, when challenged with 25RA, a dose that only induced
exencephaly in 3% of embryos of ND mice, embryos of MD mice were significantly
more susceptible to RA teratogenesis and exhibited a nine-fold increase in the
incidence rate of exencephaly. *P < 0.001, one-way ANOVA followed by Bonferroni
test. Error bars represent mean ± SEM.
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Supplementary Table 1. Blood glucose levels of non-diabetic (ND) and manifestly diabetic 
(MD) mice before pregnancy and on the day of embryo collection 
 
   
 
ND 
Before 
pregnancy 
ND 
Day of embryo 
collection (E9) 
MD 
Before 
pregnancy 
MD 
Day of embryo  
Collection (E9) 
Blood glucose 
levels (mmol/L) 
mean ± SEM 
Not determined 
 
6.08 ± 0.12 
(n = 12 ) 
21.56 ± 0.32 
(n = 101) 
27.53 ± 0.51* 
(n = 67) 
 
Remarks: 
The blood glucose levels of MD mice on the day of embryo collection at E9 were significantly 
higher than MD mice before pregnancy (*P < 0.001, Student’s t test), with none of them having 
blood glucose levels lower than 16.7 mmol/L. Similarly, there were hardly any MD mice that 
exhibited blood glucose levels lower than 16.7 mmol/L on the day of embryo collection at other 
stages (E8, E13 and E18). These findings supported that embryos of MD mice were exposed to a 
hyperglycemic milieu throughout development. 
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Supplementary Table 2. PCR conditions and primer sequences 
The PCR conditions included initiation at 95oC for 10 minutes, followed by 40 cycles 
comprising of denaturation at 95°C for 15 seconds, annealing at 55°C for 30 seconds and 
extension at 72°C for another 30 seconds. Primers sequences, designed by the Primer Express 
Software (Applied Biosystems), for detecting various mouse genes were:  
 
 
Gene Primer Sequences 
β-actin forward: 5’-TGT TAC CAA CTG GGA CGA CA-3’  
reverse: 5’-GGG GTG TTG AAG GTC TCA AA-3’  
Cdx2 forward: 5’-AAA CTC CAC TGT CAC CCA GT-3’ 
reverse: 5’-CCT GAG GTC CAT AAT TCC AC-3’ 
Cyp26a1 forward: 5’-CAG TGC TAC CTG CTC GTG AT-3’  
reverse: 5’-AGA GAA GAG ATT GCG GGT CA-3’ 
Cyp26b1 forward: 5’-TTC AGT GAG GCA AGA AGA CA-3’ 
reverse: 5’-CTG GGA GGA GGT GCT AAG TA-3’ 
Cyp26c1 forward: 5’-GGG ACC AGT TGT ATG AGC AC-3’ 
reverse: 5’-AGC CAA CTC CTT CAG CTC TT-3’ 
Fgf8 forward: 5’-AGA GAT CGT GCT GGA GAA CA-3’  
reverse: 5’-AAG GGC GGG TAG TTG AGG AA-3’ 
Rarγ forward: 5’-AGG CAG CAG ACT GAC CAT TT-3’ 
reverse: 5’-TTC TGG TAG GTG TGC AGC AG-3’ 
Rxrα forward: 5’-TCA CCA TCC TCG CCA TCT TT-3’ 
reverse: 5’-CTC CAA ACA GAG GTG CCA TG-3’ 
Wnt3a forward: 5’-CTG GCA GCT GTG AAG TGA AG-3’  
reverse: 5’-GCC TCG TAG TAG ACC AGG TC-3’ 
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Supplementary Table 3. RA in individual tailbuds of embryos of non-diabetic (ND) and 
manifestly diabetic (MD) mice 3 h post-injection of 50 mg/kg RA at E9, measured using the RA 
reporter cell line or HPLC 
 
 
 
 Amount of RA per tailbud (nM) 
Method of measurement ND MD Difference between ND and MD 
RA reporter cell line 4.21  0.13   (n = 36)* 
6.71  0.20  
 (n = 42)* 59.38% 
HPLC 7.88  0.62    (n = 7)** 
12.80  0.79  
  (n = 9)** 62.44% 
 
 
* One tailbud in each sample 
 
** Tailbuds from one litter of embryos were pooled as one sample 
 
 
Remarks: 
The data for the RA reporter cell line was extracted from Fig. 2B.  
The HPLC experiment was conducted in a separate study to validate the result in Fig. 2B. 
In analyzing the result, it is more relevant to compare the difference between ND and MD 
groups using the two RA detection methods, rather than the absolute amount of RA in the 
tailbud. 
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